The Children’s Tumor Foundation (CTF) Europe, a leader in funding and driving research in Europe into all forms of the genetic condition NF, is pleased to announce the appointment of Sabine Moravi as the newest member of its Board of Directors. Ms. Moravi brings a wealth of expertise to her CTF Europe Board role, with substantial experience in the life sciences industry as a pharma executive and in investor relations. Her valuable insights and industry knowledge will give guidance to the Foundation’s innovation goals in accelerating the development of treatments for NF patients.
Ms. Moravi, based in Switzerland, has a diverse professional background which encompasses leading the Central Europe and Nordics at Galderma, a pharmaceutical company specializing in dermatological treatments and skin care products, with full P&L responsibility. Prior to Galderma, she spent nearly two decades at Novartis in a number of pivotal roles, including as General Manager of Oncology in Austria and the Czech Republic, in roles of increasing responsibility in sales and marketing in the United States, and in Investor Relations in Switzerland and New York.
Ms. Moravi’s journey has taken her through the full spectrum of the pharmaceutical industry, from navigating the intricacies of both large-cap corporations to nimble start-ups. She’s thrived in various ownership structures, ranging from publicly-listed giants to private equity-backed enterprises and family-owned firms. She holds a masters in finance from Karl-Franzens-Universität Graz in Austria, and a Health Care Executive MBA from the University of California, Irvine.
Sabine’s dedication extends beyond her professional journey; she passionately advocates for patient-centric healthcare solutions, driven by her profound empathy for those in need. Her tireless efforts to enhance patients’ lives have been a guiding force throughout her career.
Please join us in extending a warm welcome to Sabine Moravi, to the Board of CTF Europe!
